10-K: Eli Lilly Soars on Blockbuster Drug Sales, Robust Pipeline

Eli Lilly reported exceptional financial growth in 2025, driven by strong demand for its cardiometabolic health products, while navigating a complex regulatory and competitive landscape.

Summary

• Revenue surged by 45% to $65.18 billion in 2025, up from $45.04 billion in 2024.
• Net income nearly doubled, increasing by 95% to $20.64 billion in 2025 from $10.59 billion in 2024.
• Diluted earnings per share rose by 96% to $22.95 in 2025, compared to $11.71 in 2024.
• Gross margin improved to 83.0% of revenue in 2025, a 1.7 percentage point increase from 81.3% in 2024, primarily due to favorable product mix and improved cost of production.
• Mounjaro and Zepbound were primary revenue drivers, accounting for 56% of total revenues in 2025, with Mounjaro revenue increasing 99% and Zepbound revenue increasing 175%.
• Research and development expenses increased by 21% to $13.34 billion, reflecting continued investment in early and late-stage portfolios.
• Marketing, selling, and administrative expenses increased by 29% to $11.09 billion, driven by promotional efforts for ongoing and planned product launches.
• The company made significant capital expenditures of $7.8 billion in 2025, up from $5.1 billion in 2024, for global manufacturing expansion.
• Eli Lilly acquired Verve Therapeutics for $549 million cash plus a CVR of up to $300 million, and made other significant IPR&D acquisitions totaling $2.91 billion in 2025.
• The company announced preliminary voluntary agreements with the U.S. government in November 2025 to lower Medicaid and certain other drug prices, expand Medicare access to obesity medicines by July 1, 2026, and participate in a direct-to-patient purchasing platform.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive filing, reflecting exceptional financial performance driven by blockbuster products and a robust pipeline, despite significant regulatory and competitive headwinds.

Positives

• Achieved substantial revenue growth of 45% to $65.18 billion in 2025.
• Net income and diluted EPS nearly doubled, increasing by 95% and 96% respectively.
• Gross margin improved to 83.0% of revenue, indicating strong operational efficiency and favorable product mix.
• Mounjaro and Zepbound demonstrated exceptional demand and sales growth, becoming significant revenue drivers.
• Multiple product approvals in 2025 across key therapeutic areas, including for heart failure, type 2 diabetes, Crohn's disease, early Alzheimer's, and breast cancer.
• Robust clinical development pipeline with several candidates in Phase 3 trials and regulatory review, including Orforglipron for obesity and type 2 diabetes, and Retatrutide for obesity, osteoarthritis, and OSA which met all primary and key secondary endpoints.
• Strategic acquisitions like Verve Therapeutics enhance the pipeline in genetic medicines for cardiovascular disease.
• Significant investments in manufacturing capacity expansion across multiple global sites to meet anticipated demand.
• Increased quarterly dividend to $1.73 per share for Q1 2026, indicating confidence in future financial performance.
• Repurchased $4.1 billion of shares under a $15.0 billion program, demonstrating commitment to shareholder returns.

Negatives

• Lower realized prices partially offset volume increases in 2025, particularly for Mounjaro and Zepbound.
• Increased R&D and marketing expenses, though contributing to growth, represent significant cost increases of 21% and 29% respectively.
• The effective tax rate increased to 19.8% in 2025 from 16.5% in 2024, primarily due to unfavorable jurisdictional mix of earnings and U.S. tax law changes.
• Jardiance was selected for government-set prices in Medicare effective 2026, subject to a 66% discount, and Trulicity and Verzenio were selected for government-set prices effective 2028, accelerating revenue erosion.
• Ongoing legal challenges related to 340B program, insulin pricing, and product liability for incretin medicines (Mounjaro, Trulicity, Zepbound) pose potential financial and reputational risks.
• Discontinued development of the DC-806 molecule (oral IL-17 inhibitor) acquired from DICE Therapeutics in 2024, indicating R&D failures.
• The company faces intense competition from generic and biosimilar products, as well as from counterfeit, misbranded, adulterated, and mass-compounded incretins, which impact patient safety and sales.
• Dependence on a few key products (Mounjaro and Zepbound accounted for 56% of total revenues) creates concentration risk.
• Uncertainty and risks associated with negotiating definitive agreements for voluntary U.S. government pricing arrangements, including potential delays and unfavorable terms.

Risks

• Pharmaceutical research and development is costly and highly uncertain, with a high rate of failure for new product candidates.
• Acquisitions and business development transactions involve substantial risks, including integration difficulties, failure to realize expected benefits, and regulatory scrutiny.
• Intense competition from multinational pharmaceutical companies, biotechnology companies, and generic/biosimilar manufacturers, as well as new treatment modalities.
• Market uptake of launched products and indications may not meet expectations, impacting revenue growth.
• Continued pricing pressures and actions by governmental and private payers (e.g., IRA, 340B program, formulary restrictions) could adversely affect pricing, reimbursement, and patient access.
• Product safety or efficacy concerns can arise post-approval, leading to label changes, recalls, or product liability claims.
• High dependence on a few key products (Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, Jardiance) makes the company vulnerable to factors affecting these specific products.
• Loss of intellectual property protection due to patent expirations or successful third-party challenges can lead to rapid and severe revenue declines.
• Information technology system inadequacies, security breaches, or violations of data protection laws could result in material harm to business and reputation.
• Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems, lost revenue, and increased costs.
• Reliance on third-party relationships and outsourcing arrangements introduces risks of non-performance, data breaches, and supply disruptions.
• The use of artificial intelligence (AI) and other emerging technologies presents risks related to accuracy, bias, competitive disadvantage, and evolving regulatory frameworks.
• Global operations are subject to risks from uneven economic growth, international trade disputes (e.g., tariffs), geopolitical tensions, and foreign currency fluctuations.
• Ongoing litigation and government investigations related to product pricing, safety, marketing, and intellectual property could result in significant financial and legal liabilities.
• Changes in tax laws, regulations, and increased scrutiny by tax authorities could adversely affect effective tax rates and cash flows.
• Regulatory compliance problems, including with cGMP and quality assurance, can lead to regulatory actions, product recalls, and reputational harm.
• The production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins pose patient safety risks and could impact business and reputation.

Future Outlook

Eli Lilly anticipates continued strong demand for its cardiometabolic health products, particularly Mounjaro and Zepbound, and expects additional manufacturing capacity to become operational over the next several years. The company projects near-term financial performance to be influenced by the timing of potential regulatory approvals for orforglipron and U.S. Medicare access for Zepbound and orforglipron, as well as the pace of uptake in new incretin channels and markets. Longer-term growth depends on maintaining a competitive position and delivering further innovations in its cardiometabolic health portfolio. The company expects more of its significant products to be selected for government-set prices under the IRA in future years, accelerating revenue erosion prior to exclusivity expiry. The full impact of the IRA and evolving global pricing policies on business strategies and results remains uncertain.

Management Comments

• Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
• We believe fostering a positive, inclusive culture that values the contributions of our talented colleagues helps drive our success.
• We are dedicated to ensuring that we maintain the high standards of financial accounting and reporting that we have established. We are committed to providing financial information that is transparent, timely, complete, relevant, and accurate. Our culture demands integrity and an unyielding commitment to strong internal practices and policies. Finally, we have the highest confidence in our financial reporting, our underlying system of internal controls, and our people, who are objective in their responsibilities, operate under a code of conduct and are subject to the highest level of ethical standards.

Industry Context

StockSavvy.ai notes that Eli Lilly's exceptional growth in 2025, particularly from its incretin medicines like Mounjaro and Zepbound, positions it as a leader in the highly competitive cardiometabolic health market. This performance contrasts with broader industry challenges such as increasing pricing pressures from government regulations like the Inflation Reduction Act (IRA) and the proliferation of generic and compounded alternatives. The company's aggressive investment in R&D and manufacturing expansion reflects a strategic imperative to maintain innovation and supply chain resilience amidst global competition and evolving regulatory landscapes. The focus on direct-to-patient platforms like LillyDirect also indicates a proactive approach to market access challenges, a trend observed across the pharmaceutical sector as companies seek to mitigate payer restrictions and enhance patient engagement.

Comparison to Industry Standards

• Eli Lilly's 45% revenue growth and 95% net income growth significantly outperform the average for the pharmaceutical and biotechnology industries, as indicated by the 'Current Peer Group' in the performance graph, which showed a cumulative total shareholder return of 154.11% over five years (2020-2025) compared to Lilly's 670.56%.
• The company's gross margin of 83.0% in 2025 is indicative of strong product profitability, likely driven by its high-value, patent-protected portfolio, which is generally competitive with or superior to industry averages for innovative pharmaceutical companies.
• The substantial R&D investment of $13.34 billion in 2025 demonstrates a commitment to innovation that is characteristic of leading pharmaceutical companies, aiming to replenish pipeline and sustain long-term growth, comparable to peers like Merck & Co., Inc. or Johnson & Johnson.
• The selection of Jardiance, Trulicity, and Verzenio for government-set prices under the IRA highlights the significant impact of U.S. drug pricing legislation on even market-leading products, a challenge faced by all major pharmaceutical companies operating in the U.S. market.
• The company's strategy of expanding manufacturing capacity and pursuing strategic acquisitions (e.g., Verve Therapeutics for genetic medicines) aligns with industry trends of diversifying therapeutic areas and securing supply chains, comparable to moves by companies like Amgen Inc. or AstraZeneca PLC.

Management Changes

Corporate Governance

Legal Proceedings

• Emgality Patent Litigation: Teva Pharmaceuticals alleged infringement; jury verdict for Teva in November 2022 was overruled by trial court in September 2023, finding claims invalid. Teva's appeal to the U.S. Court of Appeals for the Federal Circuit is pending.
• Brazil Litigation Cosmopolis Facility Labor Attorney Litigation: Trial court ruled against Lilly Brasil in May 2014 for alleged harm from contaminants; superior labor court significantly reduced the liquidated award in December 2025. Further appeals are possible, and a property freeze order is under appeal.
• 340B Litigation and Investigations: Lilly filed a lawsuit against HHS in January 2021 challenging its advisory opinion and ADR regulations, with an appeal pending in the U.S. Court of Appeals for the Seventh Circuit. Multiple ADR petitions are in abeyance. A class action lawsuit by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims is ongoing after the Second Circuit reversed dismissal. Lilly also sued HRSA in November 2024 over its cash replenishment model, with an appeal pending after an unfavorable district court ruling. States continue to adopt laws expanding 340B to unlimited contract pharmacies, facing ongoing constitutional challenges.
• Insulin Pricing Litigation: Multiple lawsuits since 2017 from various plaintiffs (consumers, states, etc.) alleging claims related to insulin pricing and rebates, coordinated in a multidistrict litigation (MDL). Settlements with New York and Minnesota involved no monetary payments or admission of wrongdoing. Michigan AG's investigation was dismissed and affirmed on appeal, with a state Supreme Court appeal pending.
• Average Manufacturer Price Litigation: A qui tam action alleging improper calculation of average manufacturer prices resulted in a jury verdict against Lilly in August 2022, affirmed by the Seventh Circuit in September 2025. Lilly is assessing next steps after the denial of rehearing en banc.
• Actos Litigation: A third-party payer class action alleges concealment of bladder cancer risk. Class certification was granted in May 2023, and the Ninth Circuit denied Lilly's appeal and rehearing petition in 2025. Lilly and Takeda (who indemnifies Lilly) filed a petition for certiorari to the U.S. Supreme Court in November 2025.
• Mounjaro, Trulicity, and Zepbound Product Liability Litigation: Lawsuits filed since August 2023 allege gastrointestinal injuries and non-arteritic anterior ischemic optic neuropathy (NAION) from incretin medicines, coordinated in two federal MDLs. Class action petitions are also pending in Israel and Quebec, Canada.
• Health Choice Alliance: A qui tam lawsuit under the Texas Medicaid Fraud Prevention Act, initially filed in October 2019, was purportedly dismissed and refiled in August 2025 with expanded claims across fifteen products. Lilly is opposing the dismissal of the first lawsuit.
• Research Corporation Technologies, Inc. Litigation: A lawsuit alleging breach of contract, unjust enrichment, and conversion related to manufacturing processes. A confidential agreement was reached in July 2024, with payments contingent on appeal outcomes. Lilly's appeal to the Ninth Circuit is pending.

Related Party Transactions

• Collaboration with Boehringer Ingelheim for the Jardiance product family, where Lilly receives a share of net sales and recognized $3.432 billion in revenue in 2025, including one-time benefits of $370 million from amendments to commercialization responsibilities and a $200 million sales-based milestone. Lilly is eligible for up to $910 million in potential sales-based milestones in 2026.

Stakeholder Impact

• Shareholders: Benefited from significant revenue and net income growth, increased dividends, and share repurchases. However, potential risks from litigation, regulatory pricing pressures, and product concentration could impact future returns.
• Employees: The company's commitment to fostering a positive, inclusive culture, robust training, and competitive pay and benefits aims to attract and retain a highly skilled workforce. Management changes reflect ongoing organizational evolution.
• Customers (Healthcare Providers, Patients, Payers): LillyDirect aims to expand patient access to medicines. However, pricing pressures, formulary restrictions (e.g., CVS Caremark stopping Zepbound coverage), and the availability of discounted or compounded alternatives impact access and affordability.
• Suppliers and Contract Manufacturers: Increased capital expenditures and long-term supply agreements indicate strong demand, but reliance on single-source and China-based suppliers introduces geopolitical and supply chain risks.
• Creditors: Increased total debt to $42.5 billion in 2025, but strong operating cash flow and committed credit facilities suggest adequate liquidity to manage obligations.
• Regulatory Authorities: Ongoing scrutiny and litigation related to drug pricing, 340B program, and manufacturing compliance highlight continuous interaction and potential for enforcement actions.

Next Steps

• Negotiate definitive agreements for voluntary U.S. government pricing arrangements.
• Continue to operationalize additional manufacturing capacity over the next several years.
• Seek regulatory approvals for Orforglipron (obesity, type 2 diabetes) in the U.S., EU, and Japan.
• Seek regulatory approvals for Insulin efsitora alfa (type 2 diabetes) in the U.S., EU, and Japan.
• Continue Phase 3 trials for numerous pipeline candidates across cardiometabolic health, immunology, and neuroscience.
• Monitor and respond to ongoing legal proceedings related to patent infringement, 340B program, insulin pricing, and product liability.
• Evaluate next steps in the Average Manufacturer Price qui tam action following the Seventh Circuit's denial of rehearing en banc.
• Continue to appeal the Actos litigation to the U.S. Supreme Court.
• Implement measures to lower Medicaid and certain other drug prices for U.S. patients as per preliminary voluntary agreements.
• Launch new medicines with a more balanced pricing approach across developed nations.
• Ensure Medicare beneficiaries have access to discounted Lilly obesity medicines by July 1, 2026.
• Explore new partnerships and tools to expand access to medicines, including through LillyDirect.

Key Dates

Recommendation

Eli Lilly's 2025 performance demonstrates exceptional growth, with revenue up 45% and net income nearly doubling, primarily driven by the blockbuster success of Mounjaro and Zepbound. The company boasts a robust and expanding pipeline with multiple recent approvals and promising late-stage candidates like Orforglipron and Retatrutide, backed by significant R&D and manufacturing investments. While regulatory pricing pressures (IRA) and ongoing litigation present headwinds, the company's strong financial health, strategic acquisitions, and proactive market access initiatives (LillyDirect) position it for continued leadership and long-term value creation in key therapeutic areas. The increased dividend and substantial share repurchase program further underscore management's confidence and commitment to shareholder returns, making it a strong buy for long-term investors.

Keywords

Pharmaceuticals, Biotechnology, Drug Development, Cardiometabolic Health, Obesity, Diabetes, Oncology, Immunology, Neuroscience, SEC Filing, 10-K, Eli Lilly, Mounjaro, Zepbound, Jardiance, Trulicity, Verzenio, Taltz, Kisunla, Omvoh, Orforglipron, Tirzepatide, Intellectual Property, Regulatory Affairs, Pricing Pressure, R&D, Acquisitions, Manufacturing Expansion, Corporate Governance, Legal Proceedings, Cybersecurity, AI in Pharma